Welcome to LookChem.com Sign In|Join Free
  • or
"INDEX NAME NOT YET ASSIGNED" is a chemical compound currently under investigation that has not been assigned an official name. It is a new or emerging substance that requires further testing and analysis to determine its properties, uses, and potential risks. Limited information is available about this chemical, and caution should be exercised when handling or using it. Research and regulatory agencies are working to gather more data on "INDEX NAME NOT YET ASSIGNED" to ensure its safe and proper management in the future.

796729-03-8

Post Buying Request

796729-03-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

796729-03-8 Usage

Uses

As the compound "INDEX NAME NOT YET ASSIGNED" is still under investigation, its uses have not been fully identified or established. However, once its properties and potential applications are determined, it may be used in various industries for different purposes. The following are hypothetical uses based on the information provided:
Used in Pharmaceutical Industry:
"INDEX NAME NOT YET ASSIGNED" could be used as a pharmaceutical compound for [application reason], once its therapeutic properties and safety profile are established.
Used in Chemical Industry:
"INDEX NAME NOT YET ASSIGNED" might be used as a chemical intermediate or a raw material for the synthesis of other compounds in the chemical industry, depending on its reactivity and stability.
Used in Environmental Applications:
If "INDEX NAME NOT YET ASSIGNED" is found to have properties that can be beneficial for environmental purposes, it could be used as an environmental remediation agent for [application reason], such as water or air purification.

Check Digit Verification of cas no

The CAS Registry Mumber 796729-03-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,9,6,7,2 and 9 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 796729-03:
(8*7)+(7*9)+(6*6)+(5*7)+(4*2)+(3*9)+(2*0)+(1*3)=228
228 % 10 = 8
So 796729-03-8 is a valid CAS Registry Number.

796729-03-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 5,6-Dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carboxylic acid

1.2 Other means of identification

Product number -
Other names 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carboxylic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:796729-03-8 SDS

796729-03-8Relevant academic research and scientific papers

Focal adhesion kinase inhibitor and use

-

Paragraph 0372; 0384; 0385, (2019/01/08)

The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

-

Paragraph 0546, (2015/06/25)

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS

-

Paragraph 0581, (2013/05/21)

8-Fluorophthalazin-1(2h)-one compounds of Formula II where one or two of X1, X2, and X3 are N, are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula II for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

PYRAZOLE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS

-

Page/Page column 88, (2010/04/27)

The present invention relates to a method for controlling invertebrate pests which method comprises treating the pests, their food supply, their habitat or their breeding ground or a plant, seed, soil, area, material or environment in which the pests are growing or may grow, or the materials, plants, seeds, soils, surfaces or spaces to be protected from pest attack or infestation with a pesticidally effective amount of a pyrazole compound of formulae I or II or a salt or an N-oxide thereof, wherein A is a pyrazole radical of the formulae A1 or A2, wherein # denotes the binding; D is a 5- or 6-membered heterocyclic radical fused to the pyrazole moiety; Rp1, Rp2 and Rpx are H, halogen, CN, NO2, C1-C10-alkyl, C2-C10- alkenyl, C2-C10-alkynyl, etc.; n is 0 to 4; or two radicals Rpx bound to the same ring- member may form an oxo substituent, or two radicals Rpx bound to adjacent ring- members may form a 3- to 7-membered fused cyclic radical; B is N or CR4, wherein R4 is H, halogen, CN, NO2, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, etc.; X1 is S, O or NR1a, wherein R1a is H, C1-C10-alkyl, etc.; X2 is O2a, NR2bR2c or S(O)mR2d, wherein m is 0, 1 or 2; R2a is C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, etc.; R2b, R2c are H, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, etc.; R2d is C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, etc.; R1 is H, CN, C1-C10-alkyl, C1-C10-haloalkyl, C3-C10-cycloalkyl, etc.; R2, R3 and R5 are H, halogen, CN, NO2, C1-C4-alkyl, C1-C4-haloalkyl, C1-C4-alkoxy, etc.; to a method for protecting plant propagation material and/or the plants which grow therefrom, to plant propagation material comprising at least one compound of formulae I or II, to a method for treating or protecting an animal from infestation or infection by parasites, to novel pyrazole compounds of formulae I or Il and agricultural composition containing those compounds.

Selective hydrolysis of ethyl 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2- carboxylate and ethyl 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylate as a key step in the large-scale synthesis of bicyclic heteroaryl carboxyaldehydes

Nikitenko,Winkley,Zeldis,Kremer,Chan,Strong,Jennings,Jirkovsky,Blum,Khafizova,Grosu,Venkatesan

, p. 712 - 716 (2012/12/22)

The isomeric mixture of ethyl 5,6-dihydro-4H-pyrrolo[1,2-b]-pyrazole-2- and -3-carboxylates (14 and 15), derived from a proline meso-ionic synthon, demonstrated remarkably different stabilities towards alkaline hydrolysis. On that basis, a non-chromatographic, highly efficient method for their large-scale separation was developed. The desired isomer 14 was converted into 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carbaldehyde, a key intermediate in the synthesis of bicyclic heteroaryl-substituted 6-alkylidene penems.

Process for synthesizing beta-lactamase inhibitor intermediates

-

Page 14-15, (2008/06/13)

There is provided a process for the preparation of bicyclicheteroaryl carboxaldehydes having the structural Formula I where X and Y are defined in the specification The bicyclic heteroaryl carboxaldehydes are useful as intermediates in the preparation of β-lactamase inhibitors.

Pyrazolopyrimidine derivatives

-

Page 59, (2010/01/31)

The present invention provides a compound of formula (I): where Q is a group of formula: These compounds inhibit cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDEs). More notably, the compounds are potent and selective inhibitors of the type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases and have utility therefore in a variety of therapeutic areas. In particular, the present compounds are of value for the curative or prophylactic treatment of mammalian sexual disorders.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 796729-03-8